Comparison of ketamine, 7,8-dihydroxyflavone, and ANA-12 antidepressant effects in the social defeat stress model of depression

Psychopharmacology

Volumn 232, Issue 23, 2015, Pages 4325-4335

  Zhang, Ji Chun ^a   Yao, Wei ^a   Dong, Chao ^a   Yang, Chun ^a   Ren, Qian ^a   Ma, Min ^a   Han, Mei ^a   Hashimoto, Kenji ^a  

^a CHIBA UNIVERSITY   (Japan)

Author keywords

Accumbens; AMPA receptor; Animal model; Antidepressant; BDNF; Dentate gyrus; Frontal cortex; Glutamate receptor; NMDA receptor; Stress

Indexed keywords

7,8 DIHYDROXYFLAVONE; AMIDE; AMPA RECEPTOR; BRAIN DERIVED NEUROTROPHIC FACTOR; KETAMINE; N2 [2[[(2 OXOAZEPAN 3 YL)AMINO]CARBONYL]PHENYL]BENZO[B]THIOPHENE 2 CARBOXAMIDE; POSTSYNAPTIC DENSITY PROTEIN 95; UNCLASSIFIED DRUG; 6,7-DIHYDROXYFLAVONE; ANA 12 COMPOUND; ANTIDEPRESSANT AGENT; AZEPINE DERIVATIVE; BENZAMIDE DERIVATIVE; FLAVONE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDEPRESSANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DENTATE GYRUS; DEPRESSION; DISEASE MODEL; FORCED SWIM TEST; HIPPOCAMPAL CA3 REGION; IMMOBILIZATION; MALE; MOUSE; NONHUMAN; NUCLEUS ACCUMBENS; PREFRONTAL CORTEX; PRIORITY JOURNAL; SINGLE DRUG DOSE; SOCIAL STRESS; SUCROSE PREFERENCE TEST; SYNAPTOGENESIS; TAIL SUSPENSION TEST; WESTERN BLOTTING; ANIMAL; C57BL MOUSE; COMPARATIVE STUDY; DRUG EFFECTS; HIPPOCAMPUS; MENTAL STRESS; METABOLISM; PSYCHOLOGY; SWIMMING;

ANIMALS; ANTIDEPRESSIVE AGENTS; AZEPINES; BENZAMIDES; BRAIN-DERIVED NEUROTROPHIC FACTOR; DEPRESSION; DISEASE MODELS, ANIMAL; FLAVONES; HINDLIMB SUSPENSION; HIPPOCAMPUS; KETAMINE; MALE; MICE; MICE, INBRED C57BL; NUCLEUS ACCUMBENS; PREFRONTAL CORTEX; STRESS, PSYCHOLOGICAL; SWIMMING;

EID: 84945469252     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-015-4062-3     Document Type: Article

References (61)

1. Aan Het Rot M, Zarate CA Jr, Charney DS, Mathew SJ (2012) Ketamine for depression: where do we go from here? Biol Psychiatry 72:537-547
2. Autry AE, Adachi M, Nosyreva E, Na ES, Los MF, Cheng PF, Kavalali ET, Monteggia LM (2011) NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature 475:91-95
3. Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, Krystal JH (2000) Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 47:351-354
4. Berton O, McClung CA, Dileone RJ, Krishnan V, Renthal W, Russo SJ, Graham D, Tsankova NM, Bolanos CA, Rios M, Monteggia LM, Self DW, Nestler EJ (2006) Essential role of BDNF in the mesolimbic dopamine pathway in social defeat stress. Science 311:864-868
5. Castrén E (2014) Neurotrophins and psychiatric disorders. Handb Exp Pharmacol 220:461-479
6. Cazorla M, Prémont J, Mann A, Girard N, Kellendonk C, Rognan D (2011) Identification of a low-molecular weight TrkB antagonist with anxiolytic and antidepressant activity in mice. J Clin Invest 121:1846-1857
7. Diazgranados N, Ibrahim L, Brutsche NE, Newberg A, Kronstein P, Khalife S, Kammerer WA, Quezado Z, Luckenbaugh DA, Salvadore G, Machado-Vieira R, Manji HK, Zarate CA Jr (2010) A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry 67:793-802
8. Duman RS, Aghajanian GK (2012) Synaptic dysfunction in depression: potential therapeutic targets. Science 338:68-72
9. Duman RS, Monteggia LM (2006) A neutrotrophic model for stress-related mood disorders. Biol Psychiatry 59:1116-1127
10. Dwivedi Y, Rizavi HS, Conley RR, Roberts RC, Tamminga CA, Pandey GN (2003) Altered gene expression of brain-derived neurotrophic factor and receptor tyrosin kinase B in postmortem brain of suicide subjects. Arch Gen Psychiatry 60:804-815
11. Dwyer JM, Duman RS (2013) Activation of mammalian target of rapamycin and synaptogenesis: role in the actions of rapid-acting antidepressants. Biol Psychiatry 73:1189-1198
12. Freudenberg F, Celikel T, Reif A (2015) The role of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors in depression: central mediators of pathophysiology and antidepressant activity? Neurosci Biobehav Rev 52:193-206
13. Golden SA, Covington HE III, Berton O, Russo SJ (2011) A standard protocol for repeated social defeat stress in mice. Nat Protoc 6:1183-1191
14. Hashimoto K (2009) Emerging role of glutamate in the pathophysiology of major depressive disorder. Brain Res Rev 61:105-123
15. Hashimoto K (2010) Brain-derived neurotrophic factor as a biomarker for mood disorders: an historical overview and future directions. Psychiatry Clin Neurosci 64:341-357
16. Hashimoto K (2011) The role of glutamate on the action of antidepressants. Prog Neuropsychopharmacol Biol Psychiatry 35:1558-15568
17. Hashimoto K (2013) Sigma-1 receptor chaperone and brain-derived neurotrophic factor: emerging links between cardiovascular disease and depression. Prog Neurobiol 100:15-29
18. Hashimoto K (2014) The R-stereoisomer of ketamine as an alternative for ketamine for treatment-resistant major depression. Clin Psychopharmacol Neurosci 12:72-73
19. Hashimoto K (2015) Inflammatory biomarkers as differential predictors of antidepressant response. Int J Mol Sci 16:7796-7801
20. Hashimoto K, Shimizu E, Iyo M (2004) Critical role of brain-derived neurotrophic factor in mood disorders. Brain Res Rev 45:104-114
21. Hashimoto K, Sawa A, Iyo M (2007) Increased levels of glutamate in brains from patients with mood disorders. Biol Psychiatry 62:1310-1316
22. Hashimoto K, Malchow B, Falkai P, Schmitt A (2013) Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders. Eur Arch Psychiatry Neurosci 263:367-377
23. Homberg JR, Molteni R, Calabrese F, Riva MA (2014) The serotonin-BDNF duo: developmental implications for the vulnerability to psychopathology. Neurosci Biobehav Rev 43:35-47
24. Jang SW, Liu X, Yepes M, Shepherd KR, Miller GW, Liu Y, Wilson WD, Xiao G, Blanchi B, Sun YE, Ye K (2010) A selective TrkB agonist with potent neurotrophic activities by 7,8-dihydroxyflavone. Proc Natl Acad Sci U S A 107:2687-2692
25. Karege F, Vaudan G, Schwald M, Perround N, La Harpe R (2005) Neurotrophin levels in postmortem brains of suicide victims and the effects of antemortem diagnosis and psychotropic drugs. Mol Brain Res 136:29-37
26. Koike H, Chaki S (2014) Requirement of AMPA receptor stimulation for the sustained antidepressant activity of ketamine and LY341495 during the forced swim test in rats. Behav Brain Res 271:111-115
27. Koike H, Iijima M, Chaki S (2011) Involvement of AMPA receptor in both the rapid and sustained antidepressant-like effects of ketamine in animal models of depression. Behav Brain Res 224:107-111
28. Krishnan V, Han MH, Graham DL, Berton O, Renthal W, Russo SJ, Laplant Q, Graham A, Lutter M, Lagace DC, Ghose S, Reister R, Tannous P, Green TA, Neve RL, Chakravarty S, Kumar A, Eisch AJ, Self DW, Lee FS, Tamminga CA, Cooper DC, Gershenfeld HK, Nestler EJ (2007) Molecular adaptations underlying susceptibility and resistance to social defeat in brain reward regions. Cell 131:391-404
29. Krystal JH, Sanacora G, Duman RS (2013) Rapid-acting glutamatergic antidepressants: the path to ketamine and beyond. Biol Psychiatry 73:1133-1141
30. Lepack AE, Fuchikami M, Dwyer JM, Banasr M, Duman RS (2014) BDNF release is required for the behavioral actions of ketamine. Int J Neuropsychopharmacol Oct 31;18(1) doi: 10.1093/ijnp/pyu033
31. Li N, Lee B, Liu RJ, Banasr M, Dwyer JM, Iwata M, Li XY, Aghajanian G, Duman RS (2010) mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 329:959-964
32. Li N, Liu RJ, Dwyer JM, Banasr M, Lee B, Son H, Li XY, Aghajanian G, Duman RS (2011) Glutamate N-methyl-D-aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure. Biol Psychiatry 69:754-761
33. Li SX, Zhang JC, Wu J, Hashimoto K (2014) Antidepressant effects of ketamine on depression-like behavior in juvenile mice after neonatal dexamethasone exposure. Clin Psychopharmacol Neurosci 12:124-127
34. Ma XC, Dang YH, Jia M, Ma R, Wang F, Wu J, Gao CG, Hashimoto K (2013) Long-lasting antidepressant action of ketamine, but not glycogen synthase kinase-3 inhibitor SB216763, in the chronic mild stress model of mice. PLoS One 8:e56053
35. Ma M, Ren Q, Zhang JC, Hashimoto K (2014) Effects of brilliant blue G on serum tumor necrosis factor-α levels and depression-like behavior in mice after lipopolysaccharide administration. Clin Psychopharmacol Neurosci 12:31-36
36. Maeng S, Zarate CA Jr, Du J, Schloesser RJ, McCammon J, Chen G, Manji HK (2008) Cellular mechanisms underlying the antidepressant effects of ketamine: role of α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol Psychiatry 63:349-352
37. Nestler EJ, Carlezon WA Jr (2006) The mesolimbic dopamine reward circuit in depression. Biol Psychiatry 59:1151-1159
38. Nestler EJ, Barrot M, DiLeone RJ, Eisch AJ, Gold SJ, Monteggia LM (2002) Neurobiology of depression. Neuron 34:13-25
39. Ohgi Y, Futamura T, Hashimoto K (2015) Glutamate signaling in synaptogenesis and NMDA receptors as potential therapeutic targets for psychiatric disorders. Curr Mol Med 15:206-221
40. Ren Q, Zhang JC, Fujita Y, Ma M, Wu J, Hashimoto K (2013) Effects of TrkB agonist 7,8-dihydroxyflavone on sensory gating deficits in mice after administration of methamphetamine. Pharmacol Biochem Behav 106:124-127
41. Ren Q, Zhang JC, Ma M, Fujita Y, Wu J, Hashimoto K (2014) Protective effects of TrkB agonist 7,8-dihydroxyflavone on the behavioral changes and neurotoxicity in mice after administration of methamphetamine. Psychopharmacology (Berlin) 231:159-166
42. Sanacora G, Schatzberg AF (2015) Ketamine: promising path or false prophecy in the development of novel therapeutics for mood disorders? Neuropsychopharmacology 40:259-267
43. Sanacora G, Zarate CA, Krystal JH, Manji HK (2008) Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nat Rev Drug Discov 7:426-437
44. Sato Y, Kobayashi E, Hakamata Y, Kobahashi M, Wainai T, Murayama T, Mishina M, Seo N (2004) Chronopharmacological studies of ketamine in normal and NMDA epsilon1 receptor knockout mice. Br J Anaesth 92:859-864
45. Shirayama Y, Chen AC-H, Nakagawa S, Russell DS, Duman RS (2002) Brain-derived neurotrophic factor produces antidepressant effects in behavioral models of depression. J Neurosci 22:3251-3261
46. Shirayama Y, Yang C, Zhang JC, Ren Q, Yao W, Hashimoto K (2015) Alterations in brain-derived neurotrophic factor (BDNF) and its precursor proBDNF in the brain regions of a learned helplessness rat model and the antidepressant effects of a TrkB agonist and antagonist. Eur Neuropsychopharmacol in press.
47. Skolnick P, Popik P, Trullas R (2009) Glutamate-based antidepressants: 20 years on. Trends Pharmacol Sci 30:563-569
48. Tokita K, Yamaji T, Hashimoto K (2012) Role of glutamate signaling in preclinical and/or mechanistic models of depression. Pharmacol Biochem Behav 100:688-704
49. Tsankova NM, Berton O, Renthal W, Kumar A, Neve RL, Nestler EJ (2006) Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action. Nat Neurosci 9:519-525
50. World Health Organization (WHO) (2012) Depression fact sheet No. 369/October 2012. Available at http://www.who.int/mediacentre/factsheets/fs369/en/index.html
51. Yang C, Hashimoto K (2014) Rapid antidepressant effects and abuse liability of ketamine. Psychopharmacology (Berlin) 231:2041-2042
52. Yang C, Hu YM, Zhou ZQ, Zhang GF, Yang JJ (2013) Acute administration of ketamine in rats increases hippocampal BDNF and mTOR levels during forced swimming test. Ups J Med Sci 118:3-8
53. Yang C, Shirayama Y, Zhang JC, Ren Q, Hashimoto K (2015) Regional differences in brain-derived neurotrophic factor levels and dendritic spine density confer Resilience to inescapable stress. Int J Neuropsychopharmacol 18:pyu121
54. Yao W, Zhang JC, Dong C, Zhuang C, Hirota S, Inanaga K, Hashimoto K (2015) Effects of amycenone on serum levels of tumor necrosis factor-α and depression-like behaviors in mice after administration of lipopolysaccharide. Pharmacol Biochem Behav 136:7-12
55. Zarate CA Jr, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, Charney DS, Manji HK (2006) A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 63:856-864
56. Zarate C Jr, Machado-Vieira R, Henter I, Ibrahim L, Diazgranados N, Salvadore G (2010) Glutamatergic modulators: the future of treating mood disorders? Harv Rev Psychiatry 18:293-303
57. Zarate CA Jr, Brutsche NE, Ibrahim L, Franco-Chaves J, Diazgranados N, Cravchik A, Selter J, Marquardt CA, Liberty V, Luckenbaugh DA (2012) Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. Biol Psychiatry 71:939-946
58. Zhang JC, Li SX, Hashimoto KJ (2014) R(-)-ketamine shows greater potency and longer lasting antidepressant effects than S(+)-ketamine. Pharmacol Biochem Behav 116:137-141
59. Zhang JC, Wu J, Fujita Y, Yao W, Ren Q, Yang C, Li SX, Shirayama Y, Hashimoto K (2015) Antidepressant effects of TrkB ligands on depression-like behavior and dendritic changes in mice after inflammation. Int J Neuropsychopharmacol 18:pyu077
60. Zhao T, Huang GB, Muna SS, Bagalkot TR, Jin HM, Chae HJ, Chung YC (2013) Effects of chronic social defeat stress on behavior and choline acetyltransferase, 78-kDa glucose-regulated protein, and CCAAT/enhancer-binding protein (C/EBP) homologous protein in adult mice. Psychopharmacology (Berlin) 228:217-230
61. Zhou W, Wang N, Yang C, Li XM, Zhou ZQ, Yang JJ (2014) Ketamine-induced antidepressant effects are associated with AMPA receptors-mediated upregulation of mTOR and BDNF in rat hippocampus and prefrontal cortex. Eur Psychiatry 29:419-423